hydrogen sulfide has been researched along with Hypertension, Portal in 9 studies
Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed)
hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.
thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " NaHS protected liver function, attenuated liver fibrosis, inhibited inflammation, and reduced the portal pressure, evidenced by the alterations of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), albumin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and soluble intercellular adhesion molecule (ICAM)-1, liver histology, hepatic hydroxyproline content and α-smooth muscle actin (SMA) expression." | 7.77 | Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. ( Dong, X; Jiang, H; Jiang, X; Kang, K; Kanwar, JR; Li, J; Pan, S; Qiao, H; Sun, X; Tan, G; Zhao, M, 2011) |
| "Portal hypertension is one of the most common complications contributing to the high mortality in liver cirrhosis." | 5.48 | Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats. ( Huc, T; Jaworska, K; Jurkowska, H; Onyszkiewicz, M; Ufnal, M; Wróbel, M, 2018) |
| " NaHS protected liver function, attenuated liver fibrosis, inhibited inflammation, and reduced the portal pressure, evidenced by the alterations of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), albumin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and soluble intercellular adhesion molecule (ICAM)-1, liver histology, hepatic hydroxyproline content and α-smooth muscle actin (SMA) expression." | 3.77 | Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. ( Dong, X; Jiang, H; Jiang, X; Kang, K; Kanwar, JR; Li, J; Pan, S; Qiao, H; Sun, X; Tan, G; Zhao, M, 2011) |
| "Portal hypertension is maintained by a variety of molecular mechanisms including sinusoidal endothelial cells (LSECs) hyporeactivity, activation of hepatic stellate cells (HSCs), reduction in hepatic endothelial nitric oxide synthase (eNOS) activity along with increased eNOS-derived NO generation in the splanchnic and systemic circulations." | 2.53 | Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. ( Distrutti, E; Fiorucci, S, 2016) |
| "Portal hypertension is one of the most common complications contributing to the high mortality in liver cirrhosis." | 1.48 | Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats. ( Huc, T; Jaworska, K; Jurkowska, H; Onyszkiewicz, M; Ufnal, M; Wróbel, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, C | 2 |
| Han, J | 2 |
| Li, DJ | 2 |
| Yang, Z | 2 |
| Zhang, L | 1 |
| Huc, T | 1 |
| Jurkowska, H | 1 |
| Wróbel, M | 1 |
| Jaworska, K | 1 |
| Onyszkiewicz, M | 1 |
| Ufnal, M | 1 |
| Xiao, L | 1 |
| Jin, CE | 1 |
| Renga, B | 2 |
| Cipriani, S | 1 |
| Carino, A | 1 |
| Simonetti, M | 1 |
| Zampella, A | 1 |
| Fiorucci, S | 3 |
| Distrutti, E | 2 |
| Mencarelli, A | 1 |
| Migliorati, M | 1 |
| Tan, G | 1 |
| Pan, S | 1 |
| Li, J | 1 |
| Dong, X | 1 |
| Kang, K | 1 |
| Zhao, M | 1 |
| Jiang, X | 1 |
| Kanwar, JR | 1 |
| Qiao, H | 1 |
| Jiang, H | 1 |
| Sun, X | 1 |
| Iwakiri, Y | 1 |
| Groszmann, RJ | 1 |
| Liao, JZ | 1 |
| Tian, DA | 1 |
| He, CP | 1 |
| Wang, B | 1 |
| Dan, ZL | 1 |
| Luo, M | 1 |
| Cheng, HL | 1 |
| Mei, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Concentration of Estrogen and Testosterone Ratio in Male Patients With Cirrhosis and Hypotension Compared to Male Cirrhosis Patients Without Hypotension[NCT05051293] | 0 participants (Actual) | Observational | 2021-08-22 | Withdrawn (stopped due to Study will be changed from prospective to retrospective) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydrogen sulfide and Hypertension, Portal
| Article | Year |
|---|---|
Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
Topics: Animals; Antihypertensive Agents; Cystathionine gamma-Lyase; Endothelium, Vascular; Humans; Hydrogen | 2016 |
The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.
Topics: Adrenomedullin; Animals; Biological Factors; Blood Pressure; Cannabinoid Receptor Modulators; Carbon | 2006 |
7 other studies available for hydrogen sulfide and Hypertension, Portal
| Article | Year |
|---|---|
Protective effects of hydrogen sulfide on portal hypertensive vasculopathy in rabbits by activating AKT-NF-κB pathway.
Topics: Alkynes; Animals; Antihypertensive Agents; Apoptosis; Cystathionine gamma-Lyase; Disease Models, Ani | 2017 |
Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats.
Topics: Animals; Colon; Gasotransmitters; Hydrogen Sulfide; Hypertension, Portal; Hypotension; Male; Rats, S | 2018 |
Role of hydrogen sulfide in portal hypertension and esophagogastric junction vascular disease.
Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models | 2014 |
Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1.
Topics: Animals; Bile Acids and Salts; Cholestanols; Endothelin-1; Endothelium, Vascular; Forkhead Box Prote | 2015 |
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation.
Topics: Adrenergic alpha-Agonists; Animals; Base Sequence; Bile Acids and Salts; Carbon Tetrachloride; Cell | 2009 |
Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Pressure; Carbon Tetrachloride; Cy | 2011 |
[Changes of hydrogen sulfide in portal hypertension rats].
Topics: Animals; Hydrogen Sulfide; Hypertension, Portal; Male; Rats; Rats, Sprague-Dawley | 2007 |